A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

ClinicalTrials.gov ID: NCT03192969

Public ClinicalTrials.gov record NCT03192969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Combination With Glucocorticoid Treatment Compared to Glucocorticoid Monotherapy in Adults With Giant Cell Arteritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To investigate the safety and efficacy of abatacept with steroid treatment in comparison to steroid treatment alone in up to a 28 week taper of steroid treatment to sustain remission of Giant Cell Arteritis in adults.

Study identification

NCT ID: NCT03192969
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Giant Cell Arteritis

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 50 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 15, 2017 (Estimated)
Primary completion: Jun 7, 2020 (Estimated)
Completion: Nov 23, 2021 (Estimated)
Last update posted: Jul 12, 2017

2017 – 2021

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Local Institution	Phoenix	Arizona	85032	—
Local Institution	Fullerton	California	92835	—
Local Institution	West Hollywood	California	90048	—
Local Institution	Denver	Colorado	80230	—
Local Institution	Iowa City	Iowa	52242	—
Local Institution	Kansas City	Kansas	66160	—
Local Institution	Rochester	Minnesota	55905-0001	—
Local Institution	New York	New York	10021	—
Local Institution	Cleveland	Ohio	44195	—
Local Institution	Dayton	Ohio	45417	—
Local Institution	Philadelphia	Pennsylvania	19104	—
Local Institution	Charleston	South Carolina	29406	—
Local Institution	Beaumont	Texas	77702	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03192969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 12, 2017 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03192969 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →